146 related articles for article (PubMed ID: 38241595)
1. CX3CR1 is a potential biomarker of immune microenvironment and prognosis in epithelial ovarian cancer.
Shao D; Zhou H; Yu H; Zhu X
Medicine (Baltimore); 2024 Jan; 103(3):e36891. PubMed ID: 38241595
[TBL] [Abstract][Full Text] [Related]
2. CX3CR1 Acts as a Protective Biomarker in the Tumor Microenvironment of Colorectal Cancer.
Yue Y; Zhang Q; Sun Z
Front Immunol; 2021; 12():758040. PubMed ID: 35140706
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor-1α induces CX3CR1 expression and promotes the epithelial to mesenchymal transition (EMT) in ovarian cancer cells.
Singh SK; Mishra MK; Singh R
J Ovarian Res; 2019 May; 12(1):42. PubMed ID: 31077234
[TBL] [Abstract][Full Text] [Related]
4. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Prognostic Value of MEX3A and Its Relationship with Immune Infiltrates in Ovarian Cancer.
Zhang P; Su T; Zhang S
J Immunol Res; 2021; 2021():5574176. PubMed ID: 34189143
[TBL] [Abstract][Full Text] [Related]
6. Predictive and Prognostic Implications of Circulating CX3CR1
Abdelfatah E; Long MD; Kajihara R; Oba T; Yamauchi T; Chen H; Sarkar J; Attwood K; Matsuzaki J; Segal BH; Dy GK; Ito F
Cancer Res Commun; 2023 Mar; 3(3):510-520. PubMed ID: 37009132
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of prostaglandin I2 synthase and its correlation with tumor-infiltrating immune cells in lung cancer, ovarian cancer, and gastric cancer.
Dai D; Chen B; Feng Y; Wang W; Jiang Y; Huang H; Liu J
Aging (Albany NY); 2020 May; 12(10):9658-9685. PubMed ID: 32463792
[TBL] [Abstract][Full Text] [Related]
8. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.
Yu L; Ding Y; Wan T; Deng T; Huang H; Liu J
Front Immunol; 2021; 12():768115. PubMed ID: 34966389
[TBL] [Abstract][Full Text] [Related]
9. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
10. CD38 Predicts Favorable Prognosis by Enhancing Immune Infiltration and Antitumor Immunity in the Epithelial Ovarian Cancer Microenvironment.
Zhu Y; Zhang Z; Jiang Z; Liu Y; Zhou J
Front Genet; 2020; 11():369. PubMed ID: 32425977
[TBL] [Abstract][Full Text] [Related]
11. Structure and Function of Ligand CX3CL1 and its Receptor CX3CR1 in Cancer.
Lu X
Curr Med Chem; 2022; 29(41):6228-6246. PubMed ID: 35770395
[TBL] [Abstract][Full Text] [Related]
12. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
[TBL] [Abstract][Full Text] [Related]
13. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
14. High CX3CR1 expression predicts poor prognosis in paediatric acute myeloid leukaemia undergoing hyperleukocytosis.
Mei N; Su H; Gong S; Du H; Zhang X; Wang L; Wang H
Int J Lab Hematol; 2023 Feb; 45(1):53-63. PubMed ID: 36064206
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
Zhong L; Xie L; Yang Z; Li L; Song S; Cao D; Liu Y
BMC Cancer; 2020 Aug; 20(1):766. PubMed ID: 32799825
[TBL] [Abstract][Full Text] [Related]
16. SPP1 is a prognostic related biomarker and correlated with tumor-infiltrating immune cells in ovarian cancer.
Gao W; Liu D; Sun H; Shao Z; Shi P; Li T; Yin S; Zhu T
BMC Cancer; 2022 Dec; 22(1):1367. PubMed ID: 36585688
[TBL] [Abstract][Full Text] [Related]
17. The miR-561-5p/CX
Chen EB; Zhou ZJ; Xiao K; Zhu GQ; Yang Y; Wang B; Zhou SL; Chen Q; Yin D; Wang Z; Shi YH; Gao DM; Chen J; Zhao Y; Wu WZ; Fan J; Zhou J; Dai Z
Theranostics; 2019; 9(16):4779-4794. PubMed ID: 31367257
[TBL] [Abstract][Full Text] [Related]
18. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
Front Immunol; 2019; 10():6. PubMed ID: 30761122
[No Abstract] [Full Text] [Related]
19. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
20. [The Expression of RTN1 in Lung Adenocarcinoma and
Its Effect on Immune Microenvironment].
Zhu S; Zu L; Xu S
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
